Niquitin Fruit (Nicotine Resinate)

Nicotine Resinate, the active ingredient in Niquitin Fruit, is a nicotine replacement therapy presented as an oromucosal formulation for oral use. It delivers nicotine through the mucous membranes to alleviate withdrawal symptoms and cravings in adult smokers who are attempting to quit, supporting a gradual reduction in nicotine dependence.

GNH USA supplies Niquitin Fruit as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies worldwide. The company provides reliable sourcing, regulatory support, and global logistics to meet the needs of healthcare providers.

Niquitin Fruit, a nicotine replacement therapy, is used to manage nicotine dependence and support smoking cessation.

Smoking cessation: helps adult smokers reduce withdrawal symptoms and quit tobacco use. Nicotine dependence: provides controlled nicotine delivery to lessen cravings during a quit attempt. Relapse prevention: assists individuals who have quit smoking to maintain abstinence by managing occasional urges.

Niquitin Fruit may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Mouth irritation or soreness - Nausea or upset stomach - Hiccups or throat discomfort - Dizziness or light‑headedness - Headache - Increased salivation

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Chest pain or tightness - Rapid heartbeat (tachycardia) - High blood pressure spikes - Seizures - Severe skin rash or Stevens‑Johnson syndrome

Before using Niquitin Fruit, consider the following safety measures.

Assess nicotine dependence level: evaluate patient’s smoking history before initiating therapy. Avoid use in individuals with recent myocardial infarction: consult a physician. Monitor for cardiovascular symptoms: watch for chest pain or palpitations. Do not use concurrently with other nicotine replacement products: risk of nicotine overdose. Store below 25°C: keep in the original pack, protect from moisture.

Niquitin Fruit can interact with certain medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may increase risk of hypertensive crisis. - Other nicotine‑containing products: risk of nicotine toxicity. - CYP2A6 inhibitors: can raise nicotine plasma levels.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs): may alter nicotine metabolism. - Beta‑blockers: may mask tachycardia symptoms. - Alcohol: can enhance nicotine’s cardiovascular effects.